Linked Life Data

9458489

Source:http://linkedlifedata.com/resource/pubmed/id/9458489

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
1998-2-18
pubmed:abstractText
The effects of an ACE-inhibitor (ramipril), a calcium antagonist (felodipine) and placebo on glomerular filtration rate (GFR), urinary albumin/creatinine ratio, blood pressure (BP) and vasoactive hormones were investigated in a randomized, prospective, double-blind, placebo-controlled study of patients with chronic glomerulonephritis and hypertension, with measurements at entrance and after 12 and 24 months. In total, 33 patients were included: 21 completed the study with 7 patients in each group. GFR was measured as 51Cr-EDTA clearance and the vasoactive hormones with radioimmunoassays. The reduction in GFR was significantly more pronounced in the felodipine group (-7 ml/min) than in the ramipril group (0 ml/min) but the same as in the placebo group (-6 ml/min). The urinary albumin/creatinine ratio was significantly more reduced in the ramipril group (-74 mg/mmol) than in the placebo group (-11 mg/mmol), which did not deviate from the felodipine group (-10 mg/mmol). BP was significantly reduced by ramipril and felodipine, but not by placebo. Angiotensin II and aldosterone in plasma increased or tended to increase in the felodipine and placebo groups, but were unchanged in the ramipril group. Endothelin increased only in the placebo group, and vasopressin, atrial natriuretic peptide, and brain natriuretic peptide were not significantly changed in any of the groups. It is concluded that ramipril seems to be superior to felodipine in chronic glomerulonephritis owing to better preservation of GFR.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0036-5513
pubmed:author
pubmed:issnType
Print
pubmed:volume
57
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
673-81
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:9458489-Adolescent, pubmed-meshheading:9458489-Adult, pubmed-meshheading:9458489-Aged, pubmed-meshheading:9458489-Albuminuria, pubmed-meshheading:9458489-Aldosterone, pubmed-meshheading:9458489-Angiotensin II, pubmed-meshheading:9458489-Angiotensin-Converting Enzyme Inhibitors, pubmed-meshheading:9458489-Blood Pressure, pubmed-meshheading:9458489-Calcium Channel Blockers, pubmed-meshheading:9458489-Double-Blind Method, pubmed-meshheading:9458489-Endothelins, pubmed-meshheading:9458489-Felodipine, pubmed-meshheading:9458489-Female, pubmed-meshheading:9458489-Glomerular Filtration Rate, pubmed-meshheading:9458489-Glomerulonephritis, pubmed-meshheading:9458489-Humans, pubmed-meshheading:9458489-Male, pubmed-meshheading:9458489-Middle Aged, pubmed-meshheading:9458489-Placebos, pubmed-meshheading:9458489-Prospective Studies, pubmed-meshheading:9458489-Ramipril
pubmed:year
1997
pubmed:articleTitle
A comparison of the effect of ramipril, felodipine and placebo on glomerular filtration rate, albuminuria, blood pressure and vasoactive hormones in chronic glomerulonephritis. A randomized, prospective, double-blind, placebo-controlled study over two years.
pubmed:affiliation
Aarhus University Hospital, Research Laboratory of Nephrology and Hypertension, Denmark.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't